ADDvise Group AB (publ)

Thank you and once again welcome to advice group Q4 2020 for earnings call. As usual, we will take you through a business update and then financial performance and a Q&A session. Q4 was a solid quarter. Our net sales came in at 442 million SEC, which takes us to a -on-year growth of 11%. However, we continue to see challenging pharma and clinical trials comparables following 2023 stellar performance. But we saw a clear trend shift in the quarter. That took us to a negative organic growth isolated in the quarter of minus 3% compared to last quarter where we came in at minus 25. EBITDA came in at 89 million SEC, which takes us to a 20% EBITDA margin. To give you some color on the underlying business and if we strip out pharma and clinical trials, we saw an organic growth of 7% for the year 2024. EBITDA came in at 76 million SEC versus 103, a decrease of 26, mainly due to normalized level of earn-outs reevaluation. Looking at the cash flow from operation, it came in at 64 million SEC, mainly affected by growth-related capex investments in production capacity in our South American business. Cash on hand, approximately 356 million SEC. And on the M&A side, we cautiously monitor net leverage and have that in mind on every deal that we evaluate. Coming into the commercial and operational highlights of the quarter, we saw good business momentum in both healthcare and lab during the quarter. Our acquired businesses late 2023 and early 2024 are performing according to plan or slightly above. We still saw some effects from the exceptional performance from the pharma and clinical trial business during Q4, but coming into Q1, we see a normalized level. In terms of geography, approximately 45% of our sales in the quarter isolated came from North America. And our second largest market is Europe, excluding Sweden, and the third one is South America. Looking at our sales by product category, the top three for the year are medical consumables, followed by laboratory equipment, and then medical equipment. As you can see in this pie chart, pharma is now stabilizing around 7% of our sales for the year, compared to last year when pharma was approximately around 20-25%. We see a stable demand in the US during the quarter. Our sales have been growing over the last three years. As you can see now, we are close to 1.7 billion second sales. If you look at the quarter isolated, we came in at 442 million sec, an organic drop by 3%, a significant lower level compared to previous quarter, as we see the comparable effects from pharma and clinical trials Europe fading away. We measure our revenues also in own products, products that we develop and manufacture, and products that we distribute. For last year, own products came in at 54% of our sales, and that is a level we are satisfied with going forward. Splitting advice group into healthcare and lab, and looking at healthcare, our sales came in at 275 million sec in the quarter, an organic drop of minus 1%. The lab segment reported sales of 167 million sec for the quarter, and organic sales came in at minus 10%. Margin-wise, healthcare came in at 14% EBDA margin, and lab at 30% in the quarter, isolated. Healthcare came in on the lower side, mostly affected by the product mix. We are not satisfied at all, and we are pushing hard for increasing the margins. On the other hand, lab delivered margin on the high end due to strong performance in clinical trials US and clean routes. Looking at the net sales by geography for the healthcare segment North America is the key market with approximately 60% of sales, and we continue and be that for a long time. Having said that, South America is a very fast growing market compared to the other markets that are slightly more mature, and our operations in that region is performing according to plan. During the quarter, we saw some headwinds when it comes to FX, sec versus the Brazilian real. The lab segment is very well diversified when it comes to sales by region. The largest market is now Europe, excluding Sweden. With updated long-term financial goals, we are now taking the next step in the company's development. Continuum focus on profitable growth, stable returns, and well-balanced debt levels, all based on a continued delivery on our M&A strategy. Strong focus on EBIT A growth and return on capital deployed. Compared to earlier targets that was focused on high top-line growth coupled with equity raising, we are now focused on a continued our M&A agenda driven by own generated cash flow and debt. EBIT A growth will be driven by organic and M&A related growth. This implies that our target is to double our EBIT A every fifth year. Debt level remains at max three times, and dividend is part of our framework, but it will be coming to play when the debt level and profitability is on a satisfying level. As announced in the beginning of February, we are strengthening our capital structure. A rights issue of 457 million secs combined with a warrant structure that additionally can give us up to 172 million secs next year. Of the 457 million, 326 is committed by existing shareholders, board members, and management. The transaction is scheduled to close in beginning of April. In short, we will open for shareholders to take larger share of the cash flow by lowering the financial cost. Clear target will be to replace some of the outstanding debt with bank debt over time. I'm now handing over to Johan Irve to take you through the group's financial performance.

Thank you, Stefan, and good afternoon all. I'm pleased to be here today and take you through the figures for the fourth quarter of 2024. EBITDA in the quarter amounted to 89 million secs, which corresponds to a margin of 20%. This is lower than the same period last year and is primarily driven by a change in product mix. As Stefan pointed out, we have throughout the year met exceptional comparable figures from the product segments, pharmaceuticals, and equipment to clinical trials. Which has brought down profitability compared with last year 2023. After this quarter, we are now back to normalize levels of sales and profitability. Full year 2024 EBITDA amounted to 379 million secs, which equals a margin of 23%. Moving on to cash flow and capital efficiency. Here as a reminder, when we talk about cash flow from operations, we look at the underlying cash flow generated by our businesses. With deductions from changes in working capital, as well as investments in our asset base, including lease payments and acquisition related and non-recurring items. In the fourth quarter, we saw a moderate working capital build of 5 million secs, mainly driven by increased customer receivables at the end of the year. Investments include 7 million in payments related to leases and 11 million in new fixed assets investments. If we look at the net between depreciation on existing assets and investments in new assets, it's mainly related to production capacity increase in our facilities in South America. The positive net effect of 4.8 million secs from acquisition related and non-recurring items, derived mainly from non-recurring items from the reorganization at Advice headquarters that was announced at the end of October last year. Total cash flow from operations sum up to 64 million secs. It means a cash conversion of 72% when comparing to EBITDA. Return on capital employed, which measures profitability and how efficient we use our capital, was 12% for the full year 2024. From 2025, this metric is now one of our long-term financial targets, where we aim at pushing towards 15% return on capital employed. Moving on to the balance sheet. Our financial position is currently above the long-term target of three times net debt over EBITDA. Net leverage at the end of 2024 stands at 3.8 times EBITDA. To optimize our capital structure, the Coventry plans for a rights issue of new shares that Stefan walked us through earlier. This will strengthen the balance sheet, reduce finance costs and build a solid foundation to continue our growth journey on. For reference, the Q4 net leverage, adjusted for the 457 million sec from the planned rights issue, would have reduced net leverage at the end of 2024 from 3.8 to 2.6. And even though net leverage is higher than we would like it to be, we have a good liquidity position of 356 million sec, including cash and short-term investments, plus an on-drawn credit facility. The $60 million bond issued earlier in 2024 reduces our FX exposure to USD by matching it to the asset base. The SEC bond matures in May of 2026, and the USD bond has the maturity date in April 2027. That was all from me. I will now hand over to Stefan for some closing remarks.

Thank you, Johan. I will summarize and give you our takeaways from the Q4 before we open up for questions. Sales growth at 11 in total, profitability on a normalized level, cash flow affected from investment in growth, good liquidity and too high leverage. Rights issue will be a positive thing when it comes to capital structure and leverage. On the M&A side, we are working on a couple of interesting deals. No stress. It must be right. High quality to a reasonable price tag. Good. With that summarize, I will open up for questions.

Thank you, and thanks for taking my questions. I have a couple of ones. You mentioned that you have reached more normalized levels for pharma and clinical trials. Do you expect to grow these businesses in 2025?

We always target to grow our businesses. Of course, the target is to have growth. That's clear. On the other hand, as you can imagine, given our new updated targets, it's very important for us to defend margins as well and have growth in EBITDA. We will not cut good costs in order to reach the target.

Given that pharma has shown very healthy margins historically, wouldn't it help grow in this business to reach your new financial targets?

Margin-wise, for healthcare, the expectation is higher than we had in Q4. There is potential for upside in healthcare when it comes to margins.

You mentioned that you are not satisfied with EBITDA margin levels in healthcare. What would be the normalized EBITDA margin level given that the margin has been volatile the last couple of years?

Sure. Going into this year, 2025, we will start to target and measure on the EBITDA level. It's clear that we are pushing for the 20% margin target. That is over time, of course.

You announced in November that you are exploring a potential divestment of GARMA. What is the status here? Are you still exploring this possibility?

Yes, we are. However, it's clear that the board has a decision that it's non-strategically given that there is a significant part, close to more than half of the sales is related to defense. Having said that, it's clear that we are not forced to sell. This is a very well performing company. We also see a very significant increase of the demands of their products. Having said that, we are expecting to have a rich price tag that we haven't received yet.

Okay, clear. You mentioned that half of the turnover of GARMA is within the defense sector. What is the other half? Is it within healthcare? Yes. How does the divestment of GARMA resonate with your buy and build strategy?

The thing is, we are focusing on buying and building within life science. That's clear. When the company develops and it starts to become a defense company instead of a life science, we have to re-evaluate if we should be the owner of that. Our overall target is to extend and prolong and save people's lives. I don't know if that goes hand in hand with the producing of combat suits.

Okay, that's very clear. Thank you very much. I want to jump back to the queue.

Thank you.

The next question comes from Philip Ekengren from ABGSC. Please go ahead.

Thanks and good afternoon, guys. I have a few questions. Let's start with the healthcare segment. Both orders and sales are down organically in the quarter. Could we get some more color on what's driving that more specifically, excluding the weaker generic pharmaceuticals?

Thanks. I think we still see some effects from the pharma, but on the other hand, we also see clinical trials effects in the organic, especially in the lab segment where we were down 10%.

In healthcare, is it only generic and pharma that's performing bad? Or is it other parts of that business? Okay, so as we enter 25 now, if I remember correctly, the generic pharma comp would be gone, right? So should we then expect a pickup in organic sales already in Q1 25 in healthcare specifically?

Yeah, we are set for that. And as you saw in our preliminary when we talked about December isolated, we clearly saw a pickup.

Perfect. And just coming back to the EBITDA margin, I know you said you're wanting to start focusing on EBITDA, but we have kind of history on EBITDA. So should we? What's the best representation again for healthcare as we enter 25? Is it the margin now in Q4? Is it the full year 24 margin or is it somewhere in between full year 24 and full year 23? How should we think about that? What should we extrapolate going forward?

But I can see, of course, I mean, having 2024 as a year could maybe be a representative level where we are now. Having said that, we of course, we are doing our best in order to push that and runs different initiatives in all the companies in order to increase the margins. But for now, I would say the full year margin will be more representative.

Perfect. And if we then move on to lab, orders look good in Q4 again, if I remember correctly, it was good order intake in Q3, but then the weak sales also remain. If I look at Q1 24, the comp continues to look relatively tough. How should we think about the kind of Q1 and also kind of longer in 25 in terms of organic growth in the lab segment, also with kind of this very strong order intake for some quarters now?

Yeah, and it's clear that the lab segment is affected much more when it comes to bigger project related orders, especially within clean rooms. And if you remember, I mean, Q2 last year, we had our close to if not the biggest ever. It was a really big one on this Oman order where we are from 11 million dollars or something. So it's clear that they will the bigger orders will have an effect on the sales quarter quarter.

But should we then expect growth as we enter 25 now?

Of course, of course.

Okay, good. And also, if we look at margins in lab seem to be strong quarter of a quarter. Again, walk us through just what we should expect in terms of because this as we talked about earlier, this is quite volatile. And of course, that depends on the orders you get. But how how should we model it for 25 in terms comparing it maybe to full year 24 and 23 again?

I mean, it's of course tricky, given, as I said, larger orders project will impact the quarter isolated. I mean, for Q2 comparables is of course tough when it comes to love segment. But on the other hand, we have very well performing companies. I mean, for the US clinical trials is performing very well. And that can compensate. But for me to say that it will compensate the full or not. I mean, it's it's a very tricky one for me to comment on because it's it's it's very affected on orders received. And the men to give you some I mean, we have a good pipeline within the clean room. So it's it's it's a growing business. So that's that's good for the lab segment. But to give you to give you guidance on it's very tricky, I would say. So it's it's it's a tough one. So I will. I can't do that.

Got it. Thanks guys. That was all for me. I'll get back into the line.

Thank you.

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Thank you all. And thank you for listening. Have a continuously great day. Thank you. Bye bye.